What is CRL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 14.41B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRL?

P/E (TTM) is n/a and 52-week range is $146.20 to $333.30 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRL?

The company profile lists revenue (TTM) near $4.01B, net income (TTM) near $-23.91B, EPS (TTM) near $-4.85 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Charles River Laboratories International Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmington, Massachusetts, US, 48.2M shares outstanding, ISIN US1598641074 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Charles River Laboratories International Inc

$CRL

Health Care · Life Sciences Tools & Services

IR Run Scenarios

$301.79

+1.27%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Employees

18,300

Website

www.criver.com/

IPO

2000-06-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)